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Abstract
Purpose: In vitro coagulation effects of bevacizumab, a drug with potential risks for severe hemorrhagic and
arterial thromboembolic events (ATEs), are unknown. The aim of this study was to evaluate the effects of
bevacizumab, including the common ophthalmic dose of 1.25 mg, on the coagulation cascade.
Methods: Bevacizumab doses of 0.25, 0.5, 1.0, 1.25, 2.0, 2.5, and 4.0 mg were incubated at 37C in the presence of
pooled normal plasma (PNP) to determine its biological activity via activated partial thromboplastin time (aPTT)
and prothrombin time (PT) at 30 min, 1 h, and 2 h. The control consisted of 40% normal saline and 60% PNP. All
evaluations were conducted in triplet. Coagulation at each time point was compared with the control group by
analysis of variance with Tukey’s post hoc test. A P value of £ 0.05 was considered significant.
Results: Mean bevacizumab aPTT ranged from 38.4 to 43.9 s, 37.4 to 43.1 s, and 39.0 to 43.2 s at 30 min, 1 h, and
2 h, respectively. Mean bevacizumab PT ranged from 15.7 to 16.8 s at 30 min, 14.6 to 16.2 s at 1 h, and 14.0 to
15.8 s at 2 h. For the control, aPTT was similar over time (40.1, 40.0, and 40.5 s), while PT decreased from 16.5 at
30 min to 15.4 s at 2 h. Bevacizumab decreased PT significantly at 2 h, compared with the PNP control, for the
following doses: 0.25 mg [difference between means 1.04 s, 95% confidence interval (CI) 0.12–1.96], 1.25 mg
(1.16 s, 95% CI 0.16–2.15), 2.5 mg (0.94 s, 95% CI 0.02–1.86), and 4 mg (1.41 s, 95% CI 0.41–2.40). Significant
differences were not observed in PT at 30 min and 1 h as compared with controls. For all doses of bevacizumab,
aPTT did not vary from controls at the 3 measured times.
Conclusions: A common ophthalmic dose of bevacizumab 1.25 mg significantly increased in vitro coagulation.
Further examination of the impact of ophthalmic bevacizumab on coagulation is warranted to provide insight
into any putative link between ophthalmic bevacizumab and the risk for severe ATEs.
Introduction
Bevacizumab is a humanized monoclonal antibody toanti-vascular endothelial growth factor (VEGF) and is
approved by the Food and Drug Administration to treat
a variety of neoplastic diseases.1 When given intravenously
(5 mg/kg) for chemotherapy, bevacizumab induces sys-
temic effects, which carries a risk for both hemorrhagic
and arterial thromboembolic events (ATEs).2,3 Hemorrhage
risk includes minor bleeding, most commonly Grade 1
epistaxis, and severe hemorrhage, including hemoptysis
and gastrointestinal bleeding.4 Major ATEs associated with
bevacizumab chemotherapy include cerebral infarction,
transient ischemic attacks, myocardial infarction, and
angina.4
Bevacizumab is also used off-label as an intraocular in-
jection (1.25 mg/0.05 mL) to treat a variety of ophthalmic
diseases, such as age-related macular degeneration, retinal
vein occlusion, and diabetic retinopathy.1 It is unknown,
however, whether ophthalmic doses of bevacizumab in-
crease the risk of severe hemorrhagic events or ATEs, as
well-controlled clinical trial research has yet to be con-
ducted.4,5 Recent research suggests that adverse events as-
sociated with ophthalmic bevacizumab include ATEs and
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other serious adverse reactions.6,7 The present study inves-
tigated the impact of ophthalmic doses of bevacizumab on
the coagulation cascade to provide further insight into its
potential systemic effects.
Methods
Commercially available pharmacy stock of bevacizumab
(Genentech, South San Francisco, CA; lot #761158) was re-
constituted with sterile water for injection according to the
manufacturer’s instructions. Bevacizumab doses of 0.25, 0.5,
1.0, 1.25, 2.0, 2.5, and 4.0 mg were incubated at 37C in the
presence of pooled normal plasma (PNP) to determine its
biological activity via activated partial thromboplastin time
(aPTT) and prothrombin time (PT) at 30 min, 1 h, and 2 h. The
control consisted of 40% normal saline and 60% PNP. To
obtain a dilution with 60% PNP, ophthalmic doses were
achieved in pharmacological testing dose equivalents per
milliliter. All evaluations were conducted in triplet.
Mean coagulation was calculated for each dose, as was the
difference between mean bevacizumab coagulation and
mean control coagulation. Within-dose changes between
time points were assessed using the paired t-test. Bev-
acizumab coagulation at each time point was compared with
the control group by analysis of variance with Tukey’s post
hoc test, and verified with Bonferroni methods. A P value of
£ 0.05 was considered significant. All statistical analyses
were performed using SAS (SAS Institute, Inc., Cary, NC;
Version 9.2).
Results
Mean bevacizumab aPTT ranged from 38.4 to 43.9 s, 37.4
to 43.1 s, and 39.0 to 43.2 s at 30 min, 1 h, and 2 h, respec-
tively, as shown in Table 1. Mean bevacizumab PT ranged
from 15.7 to 16.8 s at 30 min, 14.6 to 16.2 s at 1 h, and 14.0 to
15.8 s at 2 h. For the control, aPTT was similar over time
(40.1, 40.0, and 40.5 s), while PT decreased from 16.5 to 15.4 s
(P = 0.004). Within bevacizumab doses, aPTT measurements
were similar over time, except for 4.0 mg, which decreased
significantly (P = 0.006). Alternatively, PT decreased signifi-
cantly over time for all bevacizumab doses.
Compared with the PNP control, bevacizumab decreased
PT significantly at 2 h for the following doses: 0.25 mg [dif-
ference between means 1.04 s, 95% confidence interval (CI)
0.12–1.96], 1.25 mg (1.16 s, 95% CI 0.16–2.15), 2.5 mg (0.94 s,
95% CI 0.02–1.86), and 4 mg (1.41 s, 95% CI 0.41–2.40). No
significant differences were observed in PT at 30 min and 1 h
as compared with controls. For all doses of bevacizumab,
aPTT did not vary from controls at the 3 measured time
points.
Discussion
The human coagulation cascade is a series of amplification
and activation processes that occur in sequence to generate
fibrin monomers, which aggregate spontaneously to form
insoluble clots that trap platelets, red blood cells, and other
particles to form a thrombus.8 We chose to measure the ef-
fects of bevacizumab on the clotting tendency of blood using
the contact activation pathway and extrinsic coagulation
pathway, due to the ease and accessibility of the aPTT and
PT tests. The present study found that ophthalmic doses of
bevacizumab shortened PT relative to control at 2 h. De-
creased PT indicates increased in vitro coagulation, and
therefore this may be a possible mechanism for ATEs at
ophthalmic doses of bevacizumab.
VEGF is a signal protein produced by cells that stimulate
the growth of new blood vessels. VEGF induces vascular
hyperpermeability, which allows plasma proteins, such as
coagulation factors, to leak into the extracellular matrix.
Bevacizumab’s effects on vasoconstrictive and vasodilatory
factors may explain our findings that demonstrate a lower
mean PT compared with controls. Bevacizumab influ-
ences factors such as endothelin-1 and nitric oxide, which
are influenced by VEGF.9 When bevacizumab affects
vasoconstrictive and vasodilatory factors, it may increase
coagulation.9
A potential limitation of the present study is the stability
of the PNP, which can be affected as time progresses in the
processor, especially when incubated. This may explain the
observed findings of decreased 2h PT at 0.25, 1.25, 2.0, 2.5,
and 4.0 mg, but not at 0.5 or 1.0 mg doses. However, mixing
each sample immediately before analysis and running sev-
eral controls helped to minimize error. Our study compared
PT and aPTT between control and experimental samples
within each time point of interest (30 min, 1 h, and 2 h), to
control for degradation over time. All the platings and
Table 1. Trial Times of Activated Partial Thromboplastin Time and Prothrombin
Time at Varying Doses of Bevacizumab
aPTT in seconds, mean – standard deviation PT in seconds, mean– standard deviation
0.5 h 1 h 2 h 0.5 h 1 h 2 h
Control, 40% normal saline 40.1 – 1.0 40.0 – 1.0 40.5 – 0.9 16.5 – 0.9 15.5 – 0.0 15.4 – 0.9
Bevacizumab
0.25 mg 38.4 – 1.2 37.4 – 0.3 40.0 – 3.5 15.7 – 0.7 14.9 – 0.1 14.4 – 0.3a
0.5 mg 39.6 – 3.2 37.6 – 0.6 39.5 – 2.8 15.7 – 0.4 15.3 – 0.2 14.8 – 0.1
1.0 mg 43.9 – 2.3 41.9 – 4.1 43.2 – 2.3 16.5 – 0.1 16.2 – 0.1 15.8 – 0.4
1.25 mg 40.1 – 2.7 43.1 – 2.6 42.1 – 2.5 15.8 – 0.5 15.1 – 0.6 14.3 – 0.5a
2.0 mg 39.0 – 0.8 39.6 – 2.1 40.4 – 3.7 — — —
2.5 mg 40.1 – 1.5 40.6 – 1.7 40.5 – 1.6 16.1 – 0.6 15.9 – 0.3 14.5 – 0.6a
4 mg 40.6 – 1.3 39.1 – 0.4 39.0 – 0.5 16.8 – 1.2 14.6 – 0.3 14.0 – 0.1a
aStatistically significant difference compared with control (P£ 0.05).
—, no data; aPTT, activated partial thromboplastin time; PT, prothrombin time.
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readings were performed within 1 h, which is well within
the experimentally derived window of 2 h. This procedure
ensures that results accurately reflect the drug’s effects on
the PNP and not the breakdown of PNP from temperature
and time.
In summary, the present study suggests that bevacizumab
significantly affects the human coagulation cascade by in-
creasing coagulation at a common ophthalmic dose of
1.25 mg, and at both lower and higher doses. These findings
may provide a mechanism for thrombosis and underscore
the importance of further research on the effect of ophthalmic
bevacizumab on the coagulation cascade.
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